Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Kevin Kotler’s Healthcare Fund Broadfin Capital Just Had A Disastrous Q1

Though 2016 hasn’t been great for the overall hedge fund industry so far, it is turning out to be an especially terrible year for biotech-focused hedge funds. After witnessing a multi-year rally, the biopharmaceutical sector began a steep decline in the second-half of 2015 which it has yet to recover from. The severe decline that the sector has witnessed can be gauged from the returns of the S&P Pharmaceuticals Select Industry Index, which is currently trading down by over 20% this year. Among the hedge funds which have been hit the worst by this downfall is Kevin Kotler‘s Broadfin Capital. Our analysis of Broadfin Capital’s 13F holdings in companies worth at least $1 billion shows that the seven qualifying long positions held by the fund at the end of 2015 delivered a weighted average loss of 32.1% in the first quarter. Considering the magnitude of the losses suffered by the fund’s stock picks, in this article we are going to focus on its top five equity holdings going into 2016 and analyze how they have contributes to the fund’s poor performance in Q1.

We track prominent investors and hedge funds because our research has shown that historically their stock picks delivered superior risk-adjusted returns. This is especially true in the small-cap space. The 15 most popular small-cap stocks among a select group of investors delivered a monthly alpha of 80 basis points between 1999 and 2012 (see the details here).

Kevin Kotler
Kevin Kotler
Broadfin Capital

#5 Retrophin Inc (NASDAQ:RTRX)

 – Shares Owned by Broadfin Capital (as of December 31): 2.96 million

 – Value of Holding (as of December 31): $57.1 million

Amid a near 40% decline in Retrophin Inc (NASDAQ:RTRX)’s stock during the second-half of 2015, Broadfin Capital displayed its conviction in it by increasing its stake by 21% in the third quarter and a further 14% in the fourth quarter. Sadly, its conviction hasn’t paid off yet this year, as Retrophin Inc (NASDAQ:RTRX) has lost over one-fourth of its market capitalization so far in 2016. Among the funds which made the right decision by reducing their stake in the company substantially during the fourth quarter was John Overdeck and David Siegel‘s Two Sigma Advisors, which cut its holding by 42% to 114,715 shares. For the fourth quarter, Retrophin Inc (NASDAQ:RTRX) managed to beat analysts’ expectation of a loss per share of $0.22 on revenue of $29.40 million by declaring EPS of $0.07 on revenue of $30.40 million. On March 9, analysts at Leerink Swann reiterated their ‘Outperform’ rating and $27 price target on the stock, which represents a potential upside of 88% from its current price.

#4 Heron Therapeutics Inc (NASDAQ:HRTX)

 – Shares Owned by Broadfin Capital (as of December 31): 2.23 million

 – Value of Holding (as of December 31): $59.6 million

Though Broadfin Capital had reduced its stake in Heron Therapeutics Inc (NASDAQ:HRTX) by 23% during the third quarter, it turned more bullish on the company during the fourth quarter, upping its stake in the stock by 20%. Notable investors in Heron Therapeutics Inc (NASDAQ:HRTX) at the end of 2015 included billionaire Ken Griffin‘s Citadel Investment Group, which initiated its stake in the fourth quarter, purchasing 328,985 shares of the company. Though shares of Heron Therapeutics Inc have declined by almost 30% year-to-date, analysts think that they could experience a big up move if the FDA approves its preventive drug for chemotherapy-induced nausea and vomiting (CINV), SUSTOL, this month. SUSTOL has been rejected twice by the FDA, in 2010 and 2013. However, Heron Therapeutics Inc addressed the concerns raised by the FDA in the complete response letter of 2013 and resubmitted the New Drug Application for SUSTOL last July.

Follow Heron Therapeutics Inc. (NASDAQ:HRTX)
Trade (NASDAQ:HRTX) Now!

On the next page we examine three more battered stocks that dragged Broadfin Capital down during the first quarter.

Loading...